Gentle Antidepressant for Insomnia
Low-dose doxepin (3-6 mg) is the most appropriate "gentle" antidepressant for insomnia, as it is the only antidepressant with a positive recommendation from major sleep medicine guidelines and has demonstrated efficacy specifically for sleep maintenance insomnia. 1
Why Doxepin is the Answer
The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline explicitly recommends doxepin at low doses (3-6 mg) for treating sleep maintenance insomnia in adults 1. This is the only antidepressant that received a positive recommendation in these guidelines. The low doses used for insomnia are far below traditional antidepressant doses, which makes it particularly "gentle" with fewer anticholinergic side effects compared to higher doses.
When pooled across multiple studies, tricyclic antidepressants (primarily doxepin) showed:
- Moderate improvement in subjective sleep quality (SMD -0.39)
- Improved sleep efficiency by approximately 6 percentage points
- Increased total sleep time by about 23 minutes
- Little or no difference in adverse events compared to placebo 2
What NOT to Use
Trazodone is explicitly NOT recommended despite its widespread off-label use. The AASM guideline specifically states: "We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia" 1. While some research shows modest benefit, the evidence quality is insufficient to support its use 2.
SSRIs (like fluoxetine or paroxetine) have insufficient evidence for insomnia treatment, with too few studies to draw clear conclusions 2.
Clinical Algorithm
For sleep maintenance insomnia (difficulty staying asleep):
- Start doxepin 3-6 mg at bedtime 1
For sleep onset insomnia (difficulty falling asleep):
- Doxepin is less appropriate; consider non-antidepressant options like ramelteon 8 mg, zaleplon 10 mg, or zolpidem 10 mg 1
Special considerations favoring doxepin:
- Patient has comorbid depressive symptoms (not requiring full antidepressant doses)
- History of depression suggesting insomnia may be prodromal 3
- Concerns about benzodiazepine dependence
- Need for longer-term treatment 3
Important Caveats
Avoid in older adults with cognitive concerns: While doxepin at low doses has less anticholinergic activity than traditional tricyclic doses, any anticholinergic burden should be minimized in elderly patients 3.
Not first-line treatment: Cognitive behavioral therapy for insomnia (CBT-I) remains the gold standard first-line treatment 4, 5. Pharmacotherapy should be considered when CBT-I is ineffective or unavailable.
Limited long-term data: Most evidence for antidepressants in insomnia comes from short-term studies 2. The long-term safety and efficacy profile remains unclear.
Off-label use: Remember that doxepin at these low doses for insomnia is off-label use, though it has the strongest evidence base among antidepressants 3.
The evidence clearly distinguishes doxepin from other antidepressants commonly used for insomnia—it's the only one with guideline support and demonstrated efficacy without a recommendation against its use.